Author:
Berger U, ,Engelich G,Maywald O,Pfirrmann M,Hochhaus A,Reiter A,Metzgeroth G,Gnad U,Hasford J,Heinze B,Heimpel H,Hossfeld D K,Kolb H-J,Löffler H,Pralle H,Queisser W,Hehlmann R
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference28 articles.
1. Brincker H . Population-based age- and sex-specific incidence rates in the 4 main types of leukaemia. Scand J Haematol 1982; 29: 241–249.
2. National Cancer Institute (1997) Surveillance, Epidemiology, and End Results (SEER) Program. Public use CD-ROM (1973-94) released October 1997, based on the August 1996 submission. National Cancer Institute, DCPC, Surveillance Program, Cancer Statistics Branch, Bethesda, MD, USA, 1997.
3. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84: 4064–4077.
4. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86: 906–916.
5. Allan NC, Richards SM, Shepherd PC . UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995; 345: 1392–1397.
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献